DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

1994
INDEX
Alendronate, pharmacokinetics of,
1811t
ALESSE (ethinyl estradiol/
levonorgestrel), 1835t
Alfentanil hydrochloride
dosage of, 500t
pharmacokinetics of, 1811t
polymorphisms and response to,
159t
structure of, 504f
ALFERON N (interferon), 1596t
Alfuzosin, 306f, 307
pharmacokinetics of, 1811t
Aliphatic hydroxylation, 128t
Aliskiren, 745–747, 799, 1811t
Alitretinoin, 1809–1812, 1810t
Alkalinization, urinary, 85
Alkylamines, 924
Alkylated androgens, 1200–1201
Alkylating agents, 1668t–1670t
clinical pharmacology of,
1682–1684
cytotoxic actions of, 1680–1681
in dermatology, 1821
pharmacological actions of,
1680–1681
resistance to, 1681
structure-activity relationship,
1678–1680
toxicities of, 1681–1682, 1682t
Alkyl sulfonates, 1668t–1670t,
1685–1686
ALLEGRA (fexofenadine hydrochloride),
922t, 1816
Allergic contact dermatitis
glucocorticoids for, 1809
tacrolimus for, 1822
Allergic dermatoses, H 1
receptor
antagonists for, 922
Allergic reactions, as toxicity
type, 76
Allergic reactions/allergies
autocoid release and, 914
to heparin, 859
histamine in, 914
H 1
receptor antagonists for, 919,
920–922
kinins and, 931
platelet-activating factor and, 954
sympathomimetic drugs for,
302–303
Allopurinol
absorption, 996
adverse effects and side effects of,
997
Allopurinol (Cont.):
chemistry of, 996
distribution of, 996
drug interactions with, 997
elimination, 996
history of, 996
mechanism of action of, 996
pharmacokinetics of, 996, 1812t
structure of, 996
therapeutic uses of, 997
Allosteric modulators, 220
Allylamines, 1817–1818
for cutaneous fungal infection, 1818
indications for, 1816t
Almitrine, 1058
ALOCRIL (nedocromil), 1789
Alopecia
androgenetic, drugs for, 1829–1830
warfarin-induced, 864
Alopecia areata
cyclosporine for, 1821
photochemotherapy for, 1814
ALOPRIM (allopurinol), 997
ALORA (estradiol), 1839t
Alosetron
for irritable bowel syndrome, 1340
pharmacokinetics of, 1812t
Alpha-adrenergic agonists, 294–297
as anesthetic adjunct, 553
for diarrhea, 1338
local vascular effects of, 302
for nasal congestion, 302
Alpha-adrenergic receptor antagonists,
304–310
adverse effects of, 307–308
alfuzosin, 307
as antihypertensive agents, 774t,
779–780
available agents, 305–307
for benign prostatic hyperplasia, 308
bunazosin, 310
doxazosin, 307
ergot alkaloids, 310
for heart failure, 308
hemodynamic effects of, with longterm
administration, 774t
for hypertension, 308
indoramin, 310
ketanserin, 310
non-selective, 309
pharmacological properties of, 305
phenoxybenzamine, 309
phentolamine, 309
prazosin, 305–307
silodosin, 307
Alpha-adrenergic receptor antagonists
(Cont.):
tamsulosin, 307
terazosin, 307
therapeutic uses of, 308, 309–310
toxicity of, 310
urapidil, 310
yohimbine, 309
Alpha 1
-adrenergic receptor antagonists
adverse effects and side effects of, 780
as antihypertensive agents, 779–780
first-dose phenomenon with, 780
pharmacology of, 780
therapeutic uses of, 780
Alpha adrenergic receptors, 201, 203t,
207–209
Alpha-adrenergic receptors
α 1
, antidepressant potencies at, 410t
physiological basis of function of,
281–282
Alpha glucosidase inhibitors, 1265
Alpha-methyldopa. See Methyldopa
Alpha methyltyrosine, 206t
Alprazolam
pharmacokinetics of, 1812t
for pruritus, 1828t
structure of, 459t
therapeutic uses of, 466t
Alprostadil
for impotence, 952
for maintenance of patent ductus
arteriosus, 952
ALS. See Amyotrophic lateral sclerosis
(ALS)
ALTABAX (retapamulin), 1817
ALTACE (ramipril), 733, 797
Altretamine, 1685
Alzheimer’s disease (AD)
anticholinesterase agents for,
252–253
clinical overview of, 619–620
donezepil for, 253
genetics, 620
muscarinic receptors and, 223
pathophysiology of, 620–621
prevention of, NSAIDs in, 973
rivastigmine for, 253
treatment of, 621–622
Amanita muscaria, 223, 225
Amanita phalloides, 225
Amantadine, 619, 1596t, 1605–1607
dosage of, 614t
side effects of, 138t
therapeutic uses of, for Parkinson
disease, dosage of, 614t